EC approves Aegerion's lomitapide for hoFH

Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR) said the European Commission approved an MAA for Lojuxta lomitapide to treat homozygous familial hypercholesterolemia (hoFH). The small molecule microsomal triglyceride transfer protein (MTP) inhibitor is approved as an adjunct to a low-fat diet and other lipid-lowering therapies with or without LDL apheresis. Aegerion launched lomitapide in the U.S. early this year under the name Juxtapid. On Tuesday, the company reported $6.5 million in 2Q13 sales of Juxtapid that beat the Street (see BioCentury, July 30). ...